Epileptic seizure

Acute Repetitive Seizures Market Size Worth $3.19 Billion by 2025: Grand View Research, Inc.

Retrieved on: 
Monday, July 1, 2019
Articles, Economy, RTT, Medicine, Epileptic seizure, Epilepsy, Market, Emerging market

SAN FRANCISCO, July 1, 2019 /PRNewswire/ -- The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 1, 2019 /PRNewswire/ -- The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc.
  • Rise in the number of initiatives to increase the awareness about epilepsy is the major factor driving the market.
  • Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.
  • Grand View Research has segmented the global acute repetitive seizures market on the basis of product and region:
    Acute Repetitive Seizures Product Outlook (Revenue, USD Million, 2013 - 2025)

Acute Repetitive Seizures Market Size Worth $3.19 Billion by 2025: Grand View Research, Inc.

Retrieved on: 
Monday, July 1, 2019
Articles, Economy, RTT, Medicine, Epileptic seizure, Epilepsy, Market, Emerging market

SAN FRANCISCO, July 1, 2019 /PRNewswire/ -- The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 1, 2019 /PRNewswire/ -- The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc.
  • Rise in the number of initiatives to increase the awareness about epilepsy is the major factor driving the market.
  • Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.
  • Grand View Research has segmented the global acute repetitive seizures market on the basis of product and region:
    Acute Repetitive Seizures Product Outlook (Revenue, USD Million, 2013 - 2025)

Epilepsy Foundation Applauds the American Medical Association's Decision to Encourage Use of Telemedicine Programs

Retrieved on: 
Thursday, June 27, 2019
Health, Medicine, Clinical medicine, Epilepsy Foundation, Epilepsy, Epileptic seizure, Neurology, Orrin Devinsky

LANDOVER, Md., June 27, 2019 /PRNewswire/ --Epilepsy Foundation applauds the recent decision by the American Medical Association (AMA) to encourage greater use of telemedicine programs, such as Project ECHO(Extension for Community Healthcare Outcomes), to improve healthcare provider education and access to care for people in rural and underserved communities.

Key Points: 
  • LANDOVER, Md., June 27, 2019 /PRNewswire/ --Epilepsy Foundation applauds the recent decision by the American Medical Association (AMA) to encourage greater use of telemedicine programs, such as Project ECHO(Extension for Community Healthcare Outcomes), to improve healthcare provider education and access to care for people in rural and underserved communities.
  • Many primary care providers are not able to address the challenges of difficult-to-control seizures or comorbid conditions and require access to epilepsy specialists.
  • In the fall of 2019, the Epilepsy Foundation plans to expand the ECHO Epilepsy/Neurology and school nurse programs, as well as add new sessions, publish results in a medical journal, and present findings at an upcoming medical meeting for both programs.
  • The Epilepsy Foundation is leading the fight to END EPILEPSY.

Global Childhood Absence Epilepsy Treatment Market to Witness Strong Growth of Typical Absence Seizure Segment - QYR Consulting

Retrieved on: 
Monday, June 24, 2019
Health, Medicine, Clinical medicine, Seizure types, RTT, Epilepsy, Absence seizure, Epileptic seizure, Syndromes, Epilepsy syndromes

A Comprehensive assessment of the global childhood absence epilepsy treatment market is provided in this lucid report.

Key Points: 
  • A Comprehensive assessment of the global childhood absence epilepsy treatment market is provided in this lucid report.
  • Some other characteristics of the global childhood absence epilepsy treatment market are pricing strategy of the top players functioning in the market.
  • The huge economic burden of epilepsy in kids across the globe is also boosting the growth of the global childhood absence epilepsy treatment during the projected period.
  • The growing incidence of typical absence seizures in youngsters, particularly in rural areas is one of the significant factors which is creating robust growth of the global childhood absence epilepsy treatment market.

Global Childhood Absence Epilepsy Treatment Market to Witness Strong Growth of Typical Absence Seizure Segment - QYR Consulting

Retrieved on: 
Monday, June 24, 2019
Health, Medicine, Clinical medicine, Seizure types, RTT, Epilepsy, Absence seizure, Epileptic seizure, Syndromes, Epilepsy syndromes

A Comprehensive assessment of the global childhood absence epilepsy treatment market is provided in this lucid report.

Key Points: 
  • A Comprehensive assessment of the global childhood absence epilepsy treatment market is provided in this lucid report.
  • Some other characteristics of the global childhood absence epilepsy treatment market are pricing strategy of the top players functioning in the market.
  • The huge economic burden of epilepsy in kids across the globe is also boosting the growth of the global childhood absence epilepsy treatment during the projected period.
  • The growing incidence of typical absence seizures in youngsters, particularly in rural areas is one of the significant factors which is creating robust growth of the global childhood absence epilepsy treatment market.

New Research Could Help Predict Seizures Before They Happen

Retrieved on: 
Monday, June 10, 2019
Biotechnology, Nucleic acids, Branches of biology, Biology, Organic compounds, RNA, Epilepsy, Epileptic seizure, Transfer RNA, Epilepsy in animals, DNA

FutureNeuro and RCSI researchers have discovered molecules in the blood that are higher in people with epilepsy before a seizure happens.

Key Points: 
  • FutureNeuro and RCSI researchers have discovered molecules in the blood that are higher in people with epilepsy before a seizure happens.
  • These molecules are fragments of transfer RNAs (tRNAs), a chemical closely related to DNA that performs an important role in building proteins.
  • "We in FutureNeuro hope to develop a test prototype, similar to a blood sugar monitor that can potentially predict when a seizure might occur."
  • Funders of the research included Science Foundation Ireland (SFI), the European Regional Development Fund, FutureNeuro industry partners and the European Union's 'Seventh Framework' Programme FP7 (EpimiRNA).

New Research Could Help Predict Seizures Before They Happen

Retrieved on: 
Monday, June 10, 2019
Biotechnology, Nucleic acids, Branches of biology, Biology, Organic compounds, RNA, Epilepsy, Epileptic seizure, Transfer RNA, Epilepsy in animals, DNA

FutureNeuro and RCSI researchers have discovered molecules in the blood that are higher in people with epilepsy before a seizure happens.

Key Points: 
  • FutureNeuro and RCSI researchers have discovered molecules in the blood that are higher in people with epilepsy before a seizure happens.
  • These molecules are fragments of transfer RNAs (tRNAs), a chemical closely related to DNA that performs an important role in building proteins.
  • "We in FutureNeuro hope to develop a test prototype, similar to a blood sugar monitor that can potentially predict when a seizure might occur."
  • Funders of the research included Science Foundation Ireland (SFI), the European Regional Development Fund, FutureNeuro industry partners and the European Union's 'Seventh Framework' Programme FP7 (EpimiRNA).

Brain Sentinel, Inc. Announces New FDA 510(k) Clearance for its First-in-Class SPEAC® System Helping Physicians Characterize Seizure Events

Retrieved on: 
Wednesday, June 5, 2019
Epilepsy, Medicine, Health, Clinical medicine, Seizure types, Epileptic seizure

The SPEAC System is the first diagnostic platform that continuously records, analyzes, stores, and reports physiologic data for review by a physician to characterize seizure events.

Key Points: 
  • The SPEAC System is the first diagnostic platform that continuously records, analyzes, stores, and reports physiologic data for review by a physician to characterize seizure events.
  • The SPEAC System, which first received FDA De Novo clearance in February 2017, is becoming the industry-standard portable diagnostic platform for people living with epilepsy.
  • Knowing the seizure type and classification of seizure events is important to the physician's ability to make appropriate treatment plan changes.
  • In most cases, the clinician relies on seizure diaries containing eyewitness accounts of events to determine seizure type and classification.

Evogen's Cognizance Biomarkers Presents Data Showing Its Proteomic Biomarkers Have the Potential to Monitor Seizure Burden to Aid in Epilepsy Patient Management

Retrieved on: 
Tuesday, May 28, 2019
Health, Medicine, Epilepsy, Clinical medicine, Epileptic seizure, Seizure types, Syndromes

Cognizance's first product, the EvoScoreDXTM test, has demonstrated the potential to identify epileptic seizures with excellent sensitivity and specificity.

Key Points: 
  • Cognizance's first product, the EvoScoreDXTM test, has demonstrated the potential to identify epileptic seizures with excellent sensitivity and specificity.
  • The new data leverages the growing consensus that inflammation is both a cause and consequence of seizure.
  • "The impressive data presented at AEDD further validates the strength of our proteomic approach to transforming epilepsy diagnosis and management," said Todd Wallach, President and Chief Executive Officer of Evogen/Cognizance Biomarkers.
  • We look forward to advancing our proteomic tools for addressing major unmet needs in epilepsy diagnosis and management through further clinical development to full commercialization."

Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures

Retrieved on: 
Friday, May 24, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Other Health, FDA, General Health, Neurological disorders, RTT, Organ systems, Epilepsy, Clinical medicine, Seizure types, Anticonvulsants, Generalized tonic–clonic seizure, Epileptic seizure, Pregabalin, Generalized epilepsy, Primidone

The LYRICA Pediatric Epilepsy Program is composed of six studies in patients with epilepsy evaluating LYRICA as adjunctive therapy, five of which have been completed.

Key Points: 
  • The LYRICA Pediatric Epilepsy Program is composed of six studies in patients with epilepsy evaluating LYRICA as adjunctive therapy, five of which have been completed.
  • This Phase 3 study was a 12-week randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy of two doses of LYRICA in patients 5 to 65 years of age with PGTC seizures.
  • The safety profile observed in this study was comparable to the known profile of LYRICA in prior epilepsy studies in pediatric and adult patients.
  • Primary generalized tonic-clonic seizures, formerly referred to as grand mal seizures, are the most common type of generalized seizures and involve loss of consciousness.